Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia.
Secondary malignancies are an important cause of morbidity and mortality in childhood cancer survivors. Salivary gland tumors account for about 6% of the second cancers. The majority of these are mucoepidermoid carcinomas (MEC) of the parotid gland. We report the clinical and pathological features of a rarer histological type, acinic cell carcinoma (ACC), in a childhood acute lymphoblastic leukemia (ALL) survivor. The behavior of secondary ACC appears similar to primary tumor and similar treatment may be adopted. Early recognition and complete resection is important for achieving a good outcome. Careful monitoring for recurrence or a third malignancy is needed.
Cheuk
Daniel Ka Leung
DK
Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China. cheukkld@hkucc.hku.hk
Shek
Tony Wai Hung
TW
Chan
Godfrey Chi Fung
GC
Lau
Yu Lung
YL
Ha
Shau Yin
SY
Chiang
Alan Kwok Shing
AK
D006607:Adenoma, Sweat Gland / Q000209:etiology / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D018267:Carcinoma, Acinar Cell / Q000139:chemically induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009381:Neoplasms, Radiation-Induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D010307:Parotid Neoplasms / Q000139:chemically induced / Q000209:etiology* / Q000532:radiotherapy / Q000601:surgery; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D012074:Remission Induction; D017741:Survivors; D013544:Sweat Gland Neoplasms / Q000209:etiology / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014916:Whole-Body Irradiation / Q000009:adverse effects*
D003561:Cytarabine; D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin